Both authors contributed equally to this manuscript
Motor progression of Parkinson's disease with the leucine-rich repeat kinase 2 G2019S mutation
Article first published online: 5 JUN 2014
© 2014 International Parkinson and Movement Disorder Society
Volume 29, Issue 8, pages 1057–1060, July 2014
How to Cite
Yahalom, G., Orlev, Y., Cohen, O. S., Kozlova, E., Friedman, E., Inzelberg, R. and Hassin-Baer, S. (2014), Motor progression of Parkinson's disease with the leucine-rich repeat kinase 2 G2019S mutation. Mov. Disord., 29: 1057–1060. doi: 10.1002/mds.25931
Funding agencies: This study was supported by the Bharier Medical Fund, in memory of Nat and Sophie Bharier.
Relevant conflicts of interest/financial disclosures: Nothing to report.
Full financial disclosures and author roles may be found in the online version of this article.
- Issue published online: 17 JUL 2014
- Article first published online: 5 JUN 2014
- Manuscript Revised: 4 MAY 2014
- Manuscript Accepted: 4 MAY 2014
- Bharier Medical Fund
- disease progression;
- Parkinson's disease
In this retrospective study, we compared motor disease progression in Ashkenazi-Jewish (AJ) Parkinson's disease (PD) patients carrying the LRRK2*G2019S mutation with that of noncarriers.
Consecutive PD patients were recruited between 2004 and 2011. Disease progression of carriers versus noncarriers was compared using survival analysis, where the end-point was the time from PD onset to reaching Hoehn and Yahr stage 3 (HY3).
Overall, 405 AJ PD patients (males = 241[60%]) were genotyped, of whom 60 (males = 30) were LRRK2*G2019S mutation carriers. Time to HY3 did not differ significantly between mutation carriers and noncarriers (hazard ratio = 1.21, 95%CI = 0.83-1.77, P = 0.33). Age at PD onset was younger for carriers than for noncarriers (59.1 ± 9.8 vs. 63.2 ± 12.0 years, respectively; P = 0.005). In both groups, young age at onset was strongly associated with longer time to HY3, (P < 0.001).
The LRRK2*G2019S mutation status has no discernible effect on the rate of motor disease progression in AJ PD patients. © 2014 International Parkinson and Movement Disorder Society